The other three board members, Charles Fust, P. Robert DuPont, and Stacey Maloney-Fust remain as the directors of the Company.
Charles Fust, CEO of SinoFresh HealthCare, said, "We are actively seeking new board members who can assist us in our development. In particular, we want financial expertise and audit and accounting experience that can position SinoFresh for listing on the American Stock Exchange, the NASDAQ or other appropriate stock exchange. We have reached a juncture where such abilities are indispensable."
SinoFresh also announced that it has appointed Michael P. Gillette as its new Director of Marketing, Sara Byrne as its new Controller, and Gilbert Sharell as its new Director of Investor Relations.
Gillette comes to SinoFresh from Nutramax Products where he was also Director of Marketing, having been promoted from the position of product manager for that firm's line of personal care, baby care and cough-cold products. He also has worked for R.P. Scherer North America as a business development manager, Weider Nutrition Group as a brand manager, and Nature Food Centres as a marketing manager. He holds a B.S. in Business Administration from Northeastern University.
Mr. Gillette said, "I am very excited about joining SinoFresh. The opportunity here is a once-in-a-lifetime chance - to take a brand new product, not just an improved version of something else, and make it a nationwide standard for excellence."
Sara Byrne was Vice President of finance and accounting at SPEEDCOM Wireless for three years. She also has worked as accounting supervisor for Siemens ICN, Inc., as senior financial analyst at W.R. Grace and Co. and XeTel Corp., as assistant controller at CRIMI MAE, and as supervising senior accountant at KPMG Peat Marwick. She holds an M.S. in Accounting from Long Island University, a B.S. in Business Administration from the University of Florida, and is a CPA.
Gilbert Sharell was also at SPEEDCOM Wireless where he was investor relations manager for three years. Prior to that he was an analyst at Avalon Research Group and at MicroStar. He began his career at the Franklin Templeton Group, where he was an associate in the correspondence division. He holds an M.B.A. from Mercer University and a B.A. from Stetson University. His Series 6 and 7 licenses are currently inactive.
Fust said, "We are very pleased that Michael, Sara and Gilbert see the same potential for SinoFresh that we see. Each of them brings an enthusiasm and experience to our company that will serve to build the SinoFresh brand and to establish us as a nationwide firm providing a quality product that benefits both the customer and the shareholders."
About SinoFresh HealthCare, Inc.
SinoFresh HealthCare, Inc., is the developer and maker of the first over-the counter antiseptic nasal spray proven to kill germs and reduce molds responsible for chronic sinus distress. This condition affects more than 37 million Americans everyday. The Company holds several patents on its innovative pharmaceutical technology, and is involved in the Research & Development of many forms of chronic respiratory disorders. SinoFresh HealthCare, Inc., www.sinofresh.com, relies upon a distinguished panel of medical experts and a seasoned management team with years of experience in the bio-pharmaceutical arena.
The foregoing press release contains "forward-looking statements." In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of such terms and other comparable terminology. These forward-looking statements include, without limitation, statements about our market opportunity, laboratory data, collected human experience, expert opinion, traditional medical practices, our strategies, competition, expected activities and expenditures as we pursue our business plan, and the adequacy of our available cash resources. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Actual results may differ materially from the predictions discussed in our forward-looking statements. Additional factors that could materially affect our forward-looking statements include, among other things, general economic and business conditions; the future results of planned clinical trials; changes in the understanding of science and medical pathology; the success of our brand awareness campaign; our ability to raise additional capital through the offering of equity securities; competition; our ability to build strategic relationships with major retail chain stores; required accounting changes; our relationship with AccuMed; approval of our products by the FDA for OTC sales; the protection of our intellectual property rights; ensuring the commercialization of our products does not infringe upon the intellectual property rights of others; and other factors over which the Company has little or no control.